Dr. Nadeau is one of the nation’s foremost experts in adult and pediatric allergy. She is the Director of the Nadeau Laboratory at Stanford and is an endowed professor under the Naddisy Family Foundation. Her medical research and clinical practice, in addition to her accomplishments in drug development in the biotech industry, have given her the tools to manage the complex web of asthma and allergy research.
Dr. Nadeau studies the mechanisms involved in allergies to better understand how to prevent and cure the disease. She has led many clinical research studies of allergic disorders. Her work has been recognized with numerous grants and awards, and her research is part of a prestigious Clinical and Translational Science Award from the National Institutes of Health (NIH). Dr. Nadeau has received honors and awards from the American Academy of Allergy, Asthma & Immunology; the American Lung Association; the Clinical Immunological Society; Food Allergy Research & Education (FARE); and the NIH. She has also been recognized with the U.S. Environmental Protection Agency’s STAR Grant Award.
Dr. Nadeau received her MD and PhD from Harvard Medical School. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford and University of California, San Francisco. She has been a faculty member at Lucile Packard Children’s Hospital Stanford since 2006.
Dr. Nadeau is one of the nation’s foremost experts in adult and pediatric allergy. She is the Director of the Nadeau Laboratory at Stanford and is an endowed professor under the Naddisy Family Foundation. Her medical research and clinical practice, in addition to her accomplishments in drug development in the biotech industry, have given her the tools to manage the complex web of asthma and allergy research.
Dr. Nadeau studies the mechanisms involved in allergies to better understand how to prevent and cure the disease. She has led many clinical research studies of allergic disorders. Her work has been recognized with numerous grants and awards, and her research is part of a prestigious Clinical and Translational Science Award from the National Institutes of Health (NIH). Dr. Nadeau has received honors and awards from the American Academy of Allergy, Asthma & Immunology; the American Lung Association; the Clinical Immunological Society; Food Allergy Research & Education (FARE); and the NIH. She has also been recognized with the U.S. Environmental Protection Agency’s STAR Grant Award.
Dr. Nadeau received her MD and PhD from Harvard Medical School. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford and University of California, San Francisco. She has been a faculty member at Lucile Packard Children’s Hospital Stanford since 2006.
Dr Kelly is Professor of Medicine at Harvard Medical School and Chief of the Herrman L. Blumgart Internal Medicine Firm, Director of Gastroenterology Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts. Dr. Kelly has longstanding clinical and research interests in intestinal infection and inflammation. He is the author of more than 150 clinical and basic research book chapters, invited reviews, and peer-reviewed publications appearing in such journals as Infection & Immunity, American Journal of Physiology, Gastroenterology, Journal of Biological Chemistry, Journal of Clinical Investigation, The Lancet and New England Journal of Medicine. For over 20 years Dr Kelly has committed himself to finding new medical solutions to C. difficile infection, inflammatory bowel disease and Celiac Disease. He heads clinical, research and educational programs in celiac disease as Medical Director of the Celiac Center at Harvard.
Dr Kelly is Professor of Medicine at Harvard Medical School and Chief of the Herrman L. Blumgart Internal Medicine Firm, Director of Gastroenterology Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts. Dr. Kelly has longstanding clinical and research interests in intestinal infection and inflammation. He is the author of more than 150 clinical and basic research book chapters, invited reviews, and peer-reviewed publications appearing in such journals as Infection & Immunity, American Journal of Physiology, Gastroenterology, Journal of Biological Chemistry, Journal of Clinical Investigation, The Lancet and New England Journal of Medicine. For over 20 years Dr Kelly has committed himself to finding new medical solutions to C. difficile infection, inflammatory bowel disease and Celiac Disease. He heads clinical, research and educational programs in celiac disease as Medical Director of the Celiac Center at Harvard.
John Fung, MD, PhD is currently Professor of Surgery at University of Chicago. He also holds the title of Chief, Section of Transplant Surgery and is a Co-Director of the University of Chicago Medicine Transplant Institute. Dr. Fung specializes in liver transplants, hepatobiliary surgery, and transplant oncology. He has over 35 years of experience in the areas of liver and hepatobiliary malignancies, as well as kidney, pancreas, and intestinal transplantation. Dr. Fung has authored over 1,300 articles and book chapters and formerly held the position of editor-in-chief of Liver Transplantation; he continues to serve on editorial boards for several other medical journals today.
Dr. Fung has a longstanding relationship with COUR, having served on the CNP-101 Safety Committee where COUR nanoparticles were first administered to celiac patients to induce tolerance to gliadin. He now brings his deep clinical experience and expertise to our Primary Biliary Cholangitis program.
John Fung, MD, PhD is currently Professor of Surgery at University of Chicago. He also holds the title of Chief, Section of Transplant Surgery and is a Co-Director of the University of Chicago Medicine Transplant Institute. Dr. Fung specializes in liver transplants, hepatobiliary surgery, and transplant oncology. He has over 35 years of experience in the areas of liver and hepatobiliary malignancies, as well as kidney, pancreas, and intestinal transplantation. Dr. Fung has authored over 1,300 articles and book chapters and formerly held the position of editor-in-chief of Liver Transplantation; he continues to serve on editorial boards for several other medical journals today.
Dr. Fung has a longstanding relationship with COUR, having served on the CNP-101 Safety Committee where COUR nanoparticles were first administered to celiac patients to induce tolerance to gliadin. He now brings his deep clinical experience and expertise to our Primary Biliary Cholangitis program.
Dr. Gershwin is currently the Jack and Donald Chia Professor of Medicine and Distinguished Professor of Medicine at UC Davis. He was the first scientist to clone the gene that produces the autoantigen involved in the anti-mitochondrial antibody test for patients with Primary Biliary Cholangitis. He is an expert on the diagnosis and treatment of autoimmune disease and has been continuously funded by NIH for nearly 50 years. Dr. Gershwin is also a consultant for multiple federal agencies and has worked with NIH, FTC, FDA, USAID, and USDA. Dr. Gershwin is a world expert on the role of environment and health, including issues as mold, allergens, and environmental hazards.
Dr. Gershwin graduated from Stanford Medical School and interned at Tufts-New England Medical Center. He trained in immunology at the National Institutes of Health and joined the faculty of the University of California at Davis in 1975. Dr. Gershwin founded the Allergy and Clinical Immunology Program at UC Davis in 1977. He has authored over 900 experimental papers and more than 20 books.
Dr. Gershwin is currently the Jack and Donald Chia Professor of Medicine and Distinguished Professor of Medicine at UC Davis. He was the first scientist to clone the gene that produces the autoantigen involved in the anti-mitochondrial antibody test for patients with Primary Biliary Cholangitis. He is an expert on the diagnosis and treatment of autoimmune disease and has been continuously funded by NIH for nearly 50 years. Dr. Gershwin is also a consultant for multiple federal agencies and has worked with NIH, FTC, FDA, USAID, and USDA. Dr. Gershwin is a world expert on the role of environment and health, including issues as mold, allergens, and environmental hazards.
Dr. Gershwin graduated from Stanford Medical School and interned at Tufts-New England Medical Center. He trained in immunology at the National Institutes of Health and joined the faculty of the University of California at Davis in 1975. Dr. Gershwin founded the Allergy and Clinical Immunology Program at UC Davis in 1977. He has authored over 900 experimental papers and more than 20 books.
Dr. Miller is internationally known for his research on pathogenesis and regulation of autoimmune diseases and is co-inventor of the Cour toleragenic immune modifiying particle technology platform. Dr. Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago. He is a consultant to a number of biotechnology and pharmaceutical companies, having assisted in the development of three new chemical entities from proof of concept through to Phase 3 testing. He has served or currently serves on grant review panels for the National Institute of Health, the National MS Society, the Immune Tolerance Network and the Juvenile Diabetes Research Foundation and on the editorial boards of multiple journals. He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981.
His work has significantly enhanced the understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D). He was the first to describe the contribution of epitope spreading to endogenous self tissue antigens in mediating chronic CNS damage in both autoimmune [experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus-induced demyelinating disease models of MS and more recently in T1D in NOD mice. He is also noted for his work describing the cellular and molecular mechanisms underlying initiation and progression of autoimmunity by infection-induced molecular mimicry. The most widely known aspect of Dr. Miller’s scientific career has focused on the study of the cellular and molecular mechanisms underlying treatment of established T cell-mediated autoimmune diseases using antigen-specific therapies – including regulatory T cells (Tregs), short-term co-stimulatory molecule blockade strategies, and induction of immune tolerance to autoantigens induced via i.v. injection of apoptotic antigen-pulsed leukocytes and nanoparticles.
Dr. Miller is internationally known for his research on pathogenesis and regulation of autoimmune diseases and is co-inventor of the Cour toleragenic immune modifiying particle technology platform. Dr. Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago. He is a consultant to a number of biotechnology and pharmaceutical companies, having assisted in the development of three new chemical entities from proof of concept through to Phase 3 testing. He has served or currently serves on grant review panels for the National Institute of Health, the National MS Society, the Immune Tolerance Network and the Juvenile Diabetes Research Foundation and on the editorial boards of multiple journals. He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981.
His work has significantly enhanced the understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D). He was the first to describe the contribution of epitope spreading to endogenous self tissue antigens in mediating chronic CNS damage in both autoimmune [experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus-induced demyelinating disease models of MS and more recently in T1D in NOD mice. He is also noted for his work describing the cellular and molecular mechanisms underlying initiation and progression of autoimmunity by infection-induced molecular mimicry. The most widely known aspect of Dr. Miller’s scientific career has focused on the study of the cellular and molecular mechanisms underlying treatment of established T cell-mediated autoimmune diseases using antigen-specific therapies – including regulatory T cells (Tregs), short-term co-stimulatory molecule blockade strategies, and induction of immune tolerance to autoantigens induced via i.v. injection of apoptotic antigen-pulsed leukocytes and nanoparticles.
Lonnie D. Shea is a world leading biomaterial scientist and co-inventor of the Cour nanoparticle technology platform. He currently serves as a Professor in the Department of Chemical and Biological Engineering at University of Michigan. He received his BS and MS degrees in chemical engineering at Case Western Reserve University, and his PhD in Chemical Engineering and Scientific Computing while working with Jennifer Linderman at the University of Michigan, and was a postdoctoral fellow with David Mooney in the Department of Biologic and Materials Science in the Dental School at the University of Michigan.
Prior to his current role, he was on the faculty at Northwestern University where he established a research group working at the interface of tissue engineering, gene therapy, and drug delivery. He received an NSF CAREER Award in 2000, which helped start the work on developing new technologies based on combining biomaterials and gene/drug delivery. In addition, the Shea Lab works at the interface of regenerative medicine, biomaterials, and gene and drug delivery. The central theme for the various projects is creating synthetic environments which can be employed to molecularly dissect tissue formation or promote regeneration. These systems are being applied to clinical problems such as ovarian follicle maturation for treating infertility, islet transplantation for diabetes therapies, nerve regeneration for treating paralysis, and most recently, cancer diagnostics. Dr. Shea has received funding from NIH, NSF, and multiple foundations, and has published in excess of 120 manuscripts on his research. Dr. Shea is a fellow of the American Institute of Medical and Biological Engineering, and is a member of the editorial boards for Molecular Therapy, Biotechnology and Bioengineering, and Drug Delivery and Translational Research.
Lonnie D. Shea is a world leading biomaterial scientist and co-inventor of the Cour nanoparticle technology platform. He currently serves as a Professor in the Department of Chemical and Biological Engineering at University of Michigan. He received his BS and MS degrees in chemical engineering at Case Western Reserve University, and his PhD in Chemical Engineering and Scientific Computing while working with Jennifer Linderman at the University of Michigan, and was a postdoctoral fellow with David Mooney in the Department of Biologic and Materials Science in the Dental School at the University of Michigan.
Prior to his current role, he was on the faculty at Northwestern University where he established a research group working at the interface of tissue engineering, gene therapy, and drug delivery. He received an NSF CAREER Award in 2000, which helped start the work on developing new technologies based on combining biomaterials and gene/drug delivery. In addition, the Shea Lab works at the interface of regenerative medicine, biomaterials, and gene and drug delivery. The central theme for the various projects is creating synthetic environments which can be employed to molecularly dissect tissue formation or promote regeneration. These systems are being applied to clinical problems such as ovarian follicle maturation for treating infertility, islet transplantation for diabetes therapies, nerve regeneration for treating paralysis, and most recently, cancer diagnostics. Dr. Shea has received funding from NIH, NSF, and multiple foundations, and has published in excess of 120 manuscripts on his research. Dr. Shea is a fellow of the American Institute of Medical and Biological Engineering, and is a member of the editorial boards for Molecular Therapy, Biotechnology and Bioengineering, and Drug Delivery and Translational Research.